US4920129A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-ulcerative imidazopyridine compounds
Assignee: Astellas Pharma Inc
•
Filing: 1988-09-22
•
Granted: 1990-04-24
•
Expires: 2008-09-22
Abstract
Abstract The invention relates to an imidazopyridine compound of the following formula: ##STR1## wherein R 1 is lower alkynyl, R 2 is lower alkyl, R 3 is lower alkyl, R 4 is amino or acylamino, R 5 is hydrogen; lower alkyl which may be substituted by halogen, halogen; nitro; amino; acylamino; esterified carboxy; or N,N-di(lower)alkylsufamoyl, and A is lower alkylene, and pharmaceutically acceptable salts thereof, useful in the treatment of ulcers.
Inventors
- 👤 Youichi Shiokawa
- 👤 Masanobu Nagano
- 👤 Hiromichi Itani
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:42
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A; A61; A61P; A61P1/00; A61P1/04
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
61 words
An imidazopyridine compound of the following formula: ##STR5## wherein R 1 is lower alkynyl, R 2 is lower alkyl, R 3 is lower alkyl, R 4 is amino or acylamino, R 5 is hydrogen; lower alkyl which may be substituted by halogen; nitro; amino; acylamino; esterified carboxy; or N,N-di (lower)alkylsulfamoyl, and A is lower alkylene, and a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
61 words
An imidazopyridine compound of the following formula: ##STR5## wherein R 1 is lower alkynyl, R 2 is lower alkyl, R 3 is lower alkyl, R 4 is amino or acylamino, R 5 is hydrogen; lower alkyl which may be substituted by halogen; nitro; amino; acylamino; esterified carboxy; or N,N-di (lower)alkylsulfamoyl, and A is lower alkylene, and a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
10 words
A compound of claim 1, wherein R 5 is hydrogen.
Claim 4
Dependent Claim
23 words
A compound of claim 2, wherein R 4 is amino, lower alkanoylamino, acyloxy (lower)alkanoylamino, hydroxy(lower)alkanoylamino, lower alkoxycarbonylamino, ureido, lower alkylureido, thioureido or aroylthioureido.
Claim 5
Dependent Claim
22 words
A compound of claim 3, wherein R 4 is amino, lower alkanoylamino, lower alkanoyloxy(lower)alkanoylamino, hydroxy(lower)alkanoylamino, lower alkoxycarbonylamino, ureido, 3-(lower)alklureido, thioureido or 3-aroylthioureido.
Claim 6
Dependent Claim
11 words
A compound of claim 4, wherein R 4 is lower alkoxycarbonylamino.
Claim 7
Dependent Claim
26 words
A compound of claim 5, wherein R 1 is 2-propynyl, R 2 is methyl, R 3 is methyl, and R 4 is methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino.
Claim 8
Dependent Claim
8 words
A compound of claim 6, which is 8-(2-methy-6-methoxycarbonylaminobenzylamino)-3-(2-propynyl)-2-methylimidazo[1,2-a]pyridine.
Claim 9
Dependent Claim
13 words
A compound of claim 4, wherein R 4 is lower alkanoyloxy(lower)alkanoylamino or hydroxy(lower)alkanoylamino.
Claim 10
Dependent Claim
27 words
A compound of claim 8, wherein R 1 is 2-propynyl, R 2 is methyl, R 3 is methyl, and R 4 is 2-acetoxyacetylamino, 2-acetoxypropionylamino, 2-hydroxyacetylamino or 2-hydroxypropionylamino.
Claim 11
Dependent Claim
8 words
A compound of claim 9, which is 8-[2-methyl-6-(2-hydroxypropionyl)aminobenzylamino]-3-(2-propynyl)-2-methylimidazo[1,2-a]pyridine.
Claim 12
Dependent Claim
26 words
A compound of claim 1, wherein R 5 is lower alkyl which may be substituted by halogen; halogen; nitro; amino; acylamino; esterified carboxy; or N,N-di (lower)alkylsulfamoyl.
Claim 13
Dependent Claim
26 words
A compound of claim 11, wherein R 4 is lower alkoxycarbonylamino, R 5 is lower alkyl, trihalo(lower)alkyl, halogen, nitro, amino, lower alkanoylamino, lower alkoxycarbonyl or N,N-di(lower)alkylsulfamoyl.
Claim 14
Dependent Claim
28 words
An antinlcerative pharmaceutical composition which comprises an effective amount of, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
Claim 15
Dependent Claim
30 words
A method for the treatment of ulcers which comprises administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human or animal.
References Cited (Backward Citations)
US4725601A
Cited
US4831041A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-23 | 1993-10-23 | 1994-04-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-23 | 1997-10-23 | 1998-04-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-23 | 2001-10-23 | 2002-04-24 | $7700.00 | Window Closed / Lapsed |